Joten 20mg Tablet contains Teneligliptin 20mg, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By selectively inhibiting the DPP-4 enzyme, Teneligliptin enhances the levels of incretin hormones such as GLP-1 and GIP, which play a crucial role in glucose homeostasis. This mechanism leads to increased insulin secretion and decreased glucagon release in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. Joten 20mg is prescribed as an adjunct to diet and exercise to improve glycemic parameters in adult patients inadequately controlled by lifestyle modifications alone or in combination with other antidiabetic agents. The tablet is administered orally, typically once daily, with or without food, ensuring patient compliance through its convenient dosing regimen. Clinical studies have demonstrated that Teneligliptin effectively reduces HbA1c levels and fasting plasma glucose with a favorable safety profile. Common adverse effects are generally mild and may include nasopharyngitis, headache, and gastrointestinal disturbances. Caution is advised in patients with renal or hepatic impairment, and periodic monitoring of glycemic parameters is recommended to optimize therapeutic outcomes. Joten 20mg Tablet represents a valuable option in the comprehensive management of type 2 diabetes mellitus.